Aprea Therapeutics Inc (APRE) Stock Analysis

Aprea Therapeutics Inc (APRE) is a publicly traded company in the HEALTHCARE sector. It trades at $0.76, carries a market capitalization of $10.10M. This page summarizes the public market data, fundamentals, and frequently asked questions for APRE, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Aprea Therapeutics Inc currently has a Bullish sentiment score of 0.30.

About Aprea Therapeutics Inc

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, focused on advancing innovative cancer therapies by targeting the reactivation of the mutant p53 tumor suppressor protein, which plays a critical role in tumor suppression. With a diverse pipeline aimed at multiple cancer indications, Aprea is poised to make a substantial impact on the oncology market. The company’s unique therapeutic approach, combined with a steadfast dedication to enhancing pati...

GNG Research Analysis

GNG Research scores Aprea Therapeutics Inc (APRE) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for APRE.

Frequently Asked Questions

Does APRE pay dividends?

Aprea Therapeutics Inc (APRE) does not currently pay a regular dividend.

What is APRE's market cap?

Aprea Therapeutics Inc (APRE) has a market capitalization of $10.10M with a current stock price of $0.76.